Reduction of the Peripheral Blood CD56bright NK Lymphocyte Subset in FTY720-Treated Multiple Sclerosis Patients
Open Access
- 1 July 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 187 (1) , 570-579
Abstract
FTY720 (fingolimod) treatment of multiple sclerosis (MS) results in lymphopenia due to increased recruitment into and decreased egress from secondary lymphoid organs of CCR7+ lymphocytes. Although absolute numbers of NK lymphocytes were reported as being unaltered in FTY720-treated MS patients (MS-FTY), such analyses did not detect a change in a minor subset. Because expression of CCR7 has been described on CD56bright NK cells, a minority population of NK cells, we investigated the effect of FTY720 treatment on the phenotype and function of human NK cells in the peripheral circulation of MS patients. MS-FTY patients displayed a decreased proportion of peripheral CD56brightCD62L+CCR7+ NK cells compared with untreated MS and healthy donors. In vitro treatment with FTY720-P increased migration of untreated donor NK cells to CXCL12 while reducing the response to CX3CL1 with similar migration responses seen in NK cells from MS-FTY patients. FTY720-P inhibited sphingosine 1-phosphate–directed migration of CD56bright and CD56dim NK cells subsets from untreated healthy donors. IL-12– and IL-15–stimulated NK cells from MS-FTY patients displayed similar capacity to produce IFN-γ, TNF, IL-10, and MIP-1α cytokines/chemokines compared with NK cells from untreated healthy donors and displayed comparable levels of degranulation in response to K562 tumor cells compared with untreated donors. Subset alterations and function of NK cell populations will need to be considered as part of assessing overall immunosurveillance capacity of patients with MS who will receive sustained FTY720 therapy.Keywords
This publication has 46 references indexed in Scilit:
- An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2–Driven Activation of CD56bright NK CellsThe Journal of Immunology, 2010
- Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kineticsJournal of Experimental Medicine, 2010
- Education of human natural killer cells by activating killer cell immunoglobulin-like receptorsBlood, 2010
- FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous systemBritish Journal of Pharmacology, 2009
- T-bet–dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrowJournal of Experimental Medicine, 2009
- CD56bright natural killer (NK) cells: an important NK cell subsetImmunology, 2009
- The role of natural killer cells in curbing neuroinflammationJournal of Neuroimmunology, 2007
- Matrix Metalloproteinase-1 Produced by Human CXCL12-Stimulated Natural Killer CellsThe American Journal of Pathology, 2006
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences of the United States of America, 2006
- FTY720 treatment of kidney transplant patients: A differential effect on B cells, naïve T cells, memory T cells and NK cellsTransplant Immunology, 2006